Braden Pressure Ulcer Scale for Prediction of the Intensive Care Length of Stay (BRILS)

July 25, 2025 updated by: Cihangir Doğu, Ankara City Hospital Bilkent

The Effect of the Braden Pressure Ulcer Scale on the Prediction of Intensive Care Unit Length of Stay

The aim of this study is to predict the length of intensive care unit stay of patients treated in a tertiary general intensive care unit with the help of the Braden risk assesment scale, which is used to predict the risk of pressure ulcers. The main question it aims to answer is:

  • Does high Braden scales predict the long lenght of stay? Braden scales of patients admitted to the intensive care unit were recorded every day.

Study Overview

Status

Completed

Conditions

Detailed Description

Intensive care units are specialized units where patients with multiple comorbidities are treated. The length of stay in intensive care varies according to the characteristics of the patient, the disease and the center. Prolonged intensive care stay causes an increase in mortality . It has been reported that the severity of the disease as well as the comorbidities of the patients contribute to prolonged stay . One third of patients with stay longer than seven days were evaluated as more fragile than before hospital admission. Prolonged intensive care length of stay leads to an increase in morbidity and mortality, bed demand and costs.

The Braden pressure ulcer scale was developed by Braden et al. in 1987 . Scoring is done under six different headings evaluating sensory perception, humidity, activity, mobility, nutrition and friction/cutting. It has been reported as an effective tool for evaluating pressure ulcer development in intensive care patients. In this scoring system, there are different assessment steps such as mobility, nutrition, sensory perception, etc., which allows the assessment of the functional capacity of the patients at the time of admission. In a study of elderly dementia patients, the Braden scale was found to be effective in predicting 90-day mortality. In a retrospective evaluation of patients with heart failure, the Braden scale was reported to predict 30-day mortality.

The aim of our study is to predict the length of intensive care stay by analyzing the Braden scales calculated on the day of hospitalization.

Study Type

Observational

Enrollment (Actual)

11000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Turkey
      • Ankara, Turkey
        • Ankara Bilkent City Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Medical and surgical intensive care patients admitted to the tertiary general intensive care unit of Ankara Bilkent City Hospital

Description

Inclusion Criteria:

  • Patients older than 18 years
  • Patients treated in intensive care
  • Patients treated with diagnoses other than Covid-19
  • Patients without missing data in the hospital electronic data system
  • Patients hospitalized for more than 24 hours

Exclusion Criteria:

  • Patients younger than 18 years
  • Patients treated for Covid-19 disease
  • Patients with missing data in the hospital electronic data system
  • Patients hospitalized for less than 24 hours

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Group I
Intensive Care patients admitted to tertiary intensive care unit and treated more than 24 hours

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Intensive care length of stay
Time Frame: Time period between patient admission to intensive care unit and patient discharge, patient transfer to ward or patient death, whichever came first. Estimated time up to 52 weeks
Patient intensive care length of stay
Time period between patient admission to intensive care unit and patient discharge, patient transfer to ward or patient death, whichever came first. Estimated time up to 52 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Mortality
Time Frame: Time interval between patient intensive care unit admission to patient mortality. Estimated time is up to 52 weeks
All-cause mortality rate in the intensive care unit.
Time interval between patient intensive care unit admission to patient mortality. Estimated time is up to 52 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Ankara City Hospital Bilkent

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 2025

Primary Completion (Actual)

May 31, 2025

Study Completion (Actual)

May 31, 2025

Study Registration Dates

First Submitted

November 15, 2024

First Submitted That Met QC Criteria

November 18, 2024

First Posted (Actual)

November 20, 2024

Study Record Updates

Last Update Posted (Actual)

July 28, 2025

Last Update Submitted That Met QC Criteria

July 25, 2025

Last Verified

January 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • TABED 2-24-618

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Length of ICU Stay

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malta

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe